MCM
IMCR icon

MAI Capital Management’s Immunocore IMCR Stock Holding History

MAI Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-742
Closed -$22.4K – 3350
2026
Q1 		$22.4K Hold
742
– – ﹤0.01% 2730
2025
Q4 		$25.8K Buy
+742
New +$26.2K ﹤0.01% 2384

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

MAI Capital Management's IMCR Position: Q2 2026 in Review

MAI Capital Management sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 742 shares — an estimated $22.4K sold.

MAI Capital Management first reported a position in IMCR in Q4 2025 and held it in 2 quarters. The position peaked at $25.8K in Q4 2025. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • MAI Capital Management reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 742 Immunocore shares in Q2 2026, an estimated $22.4K.
  • MAI Capital Management first reported a position in Immunocore in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Immunocore position peaked at $25.8K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.